Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 150 No. 2728 (2020)

Osteogenesis imperfecta: towards an individualised interdisciplinary care strategy to improve physical activity and quality of life

DOI
https://doi.org/10.4414/smw.2020.20285
Cite this as:
Swiss Med Wkly. 2020;150:w20285
Published
06.07.2020

Abstract

BACKGROUND

This report describes a new strategy for the care of patients with osteogenesis imperfecta, based on an interdisciplinary team working. Thereby, we aim at fulfilling three main goals: offering thorough coordinated management for all, and improving physical activity and quality of life of the patients.

AIM

With rare diseases such as osteogenesis imperfecta (OI), patients and their family often suffer from inadequate recognition of their disease, poor care coordination and incomplete information. A coordinated interdisciplinary approach is one possible solution for providing both comprehensive and cost-effective care, with benefits for patient satisfaction. Poor physical activity and impaired quality of life represent a considerable burden for these patients. To better address these issues, in 2012 we created an interdisciplinary team for the management of OI patients in our University Hospital Centre (CHUV, Lausanne University Hospital,). In this article we describe the implementation of this interdisciplinary care strategy for patients suffering from OI, and its impact on their physical activity and quality of life.

METHODS

All patients from the French part of Switzerland were invited to join us. We proposed two complementary evaluations: the initial interdisciplinary evaluation and a yearly follow-up during a special day – the “OI day”. This day features specialised medical appointments adapted to each patient’s needs, as well as lectures and/or workshops dedicated to patients’ and families’ education. Our first aim was to propose for each patient the same management, from diagnosis to the bone health evaluation and physical therapy advice. Our second aim was to evaluate the evolution of physical activity, quality of life (measured by EQ-5D, SF-36 and a dedicated questionnaire) and satisfaction of patients and their families. Here we report both the initial and the long-term results.

RESULTS

Since 2012, 50 patients from the French part of Switzerland received the personalised medical evaluation. All of the patients included in this study had the same initial evaluation and at least one participation in an OI Day. All patients had an adaptation of their bone acting drugs. Over a 7-year period, 62% of inactive patients started some physical activity, and 44% of patients who were not involved in any athletic activity started participating in sports. The mean EQ-5D increased from 0.73 to 0.75 (p = 0.59). The mean physical SF36 (musculoskeletal function) score was 59.09 ± 22.72 and improved to 65.79 ± 21.51 (p = 0.08), whereas it was 68.06 ± 20.05 for the mental SF36 without alteration during follow-up. The OI day was revealed to be useful, it contributed to improvement in continuity of care and helped families to better understand the OI patients’ health.

CONCLUSIONS

Our interdisciplinary approach aimed at offering the same thorough management for all patients from the French part of Switzerland, and at improving both the physical activity and the satisfaction of the patients and their family. This report is a basis for future work focusing on the effect of bone fragility and the impact of OI on patients’ social relations.

References

  1. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7(9):540–57. doi:.https://doi.org/10.1038/nrendo.2011.81
  2. Hald JD, Folkestad L, Swan CZ, Wanscher J, Schmidt M, Gjørup H, et al. Osteogenesis imperfecta and the teeth, eyes, and ears-a study of non-skeletal phenotypes in adults. Osteoporos Int. 2018;29(12):2781–9. doi:.https://doi.org/10.1007/s00198-018-4663-x
  3. Pillion JP, Vernick D, Shapiro J. Hearing loss in osteogenesis imperfecta: characteristics and treatment considerations. Genet Res Int. 2011;2011:983942. doi:.https://doi.org/10.4061/2011/983942
  4. Bregou Bourgeois A, Aubry-Rozier B, Bonafé L, Laurent-Applegate L, Pioletti DP, Zambelli PY. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly. 2016;146:w14322.
  5. Harsevoort AGJ, Gooijer K, van Dijk FS, van der Grijn DAFM, Franken AAM, Dommisse AMV, et al. Fatigue in adults with Osteogenesis Imperfecta. BMC Musculoskelet Disord. 2020;21(1):6. doi:.https://doi.org/10.1186/s12891-019-3000-7
  6. Hill CL, Baird WO, Walters SJ. Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study. Health Qual Life Outcomes. 2014;12(1):54. doi:.https://doi.org/10.1186/1477-7525-12-54
  7. Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. J Multidiscip Healthc. 2017;10:145–55. doi:.https://doi.org/10.2147/JMDH.S113483
  8. Lafage-Proust MH, Courtois I. The management of osteogenesis imperfecta in adults: state of the art. Joint Bone Spine. 2019;86(5):589–93. doi:.https://doi.org/10.1016/j.jbspin.2019.02.001
  9. Swezey T, Reeve BB, Hart TS, Floor MK, Dollar CM, Gillies AP, et al. Incorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta community. Osteoporos Int. 2019;30(2):507–11. doi:.https://doi.org/10.1007/s00198-018-4690-7
  10. Aubry-Rozier B, Unger S, Bregou A, Freymond Morisod M, Vaswani A, Scheider P, et al. [News in osteogenesis imperfecta: from research to clinical management]. Rev Med Suisse. 2015;11(466):657–8, 660–2. Article in French.
  11. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164(6):1470–81. doi:.https://doi.org/10.1002/ajmg.a.36545
  12. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101–16. doi:.https://doi.org/10.1136/jmg.16.2.101
  13. Fayer PMD. Quality of Life. The assessment, analysis and interpretation of patient-reported outcomes. 2nd edition. Chichester: John Wiley and Sons Ltd; 2007.
  14. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43. doi:.https://doi.org/10.3109/07853890109002087
  15. Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013;14(1):57–66. doi:.https://doi.org/10.1007/s10198-011-0351-x
  16. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83. doi:.https://doi.org/10.1097/00005650-199206000-00002
  17. Stalfors J, Lundberg C, Westin T. Quality assessment of a multidisciplinary tumour meeting for patients with head and neck cancer. Acta Otolaryngol. 2007;127(1):82–7. doi:.https://doi.org/10.1080/00016480600740589
  18. van Hagen P, Spaander MC, van der Gaast A, van Rij CM, Tilanus HW, van Lanschot JJ, et al.; Rotterdam Oesophageal Tumour Study Group. Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study. Int J Clin Oncol. 2013;18(2):214–9. doi:.https://doi.org/10.1007/s10147-011-0362-8
  19. Folkestad L, Hald JD, Hansen S, Gram J, Langdahl B, Abrahamsen B, et al. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. J Bone Miner Res. 2012;27(6):1405–12. doi:.https://doi.org/10.1002/jbmr.1592
  20. Kocijan R, Muschitz C, Haschka J, Hans D, Nia A, Geroldinger A, et al. Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta. Osteoporos Int. 2015;26(10):2431–40. doi:.https://doi.org/10.1007/s00198-015-3156-4
  21. Takken T, Terlingen HC, Helders PJ, Pruijs H, Van der Ent CK, Engelbert RH. Cardiopulmonary fitness and muscle strength in patients with osteogenesis imperfecta type I. J Pediatr. 2004;145(6):813–8. doi:.https://doi.org/10.1016/j.jpeds.2004.08.003
  22. Engelbert RH, Uiterwaal CS, Gerver WJ, van der Net JJ, Pruijs HE, Helders PJ. Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. Arch Phys Med Rehabil. 2004;85(5):772–8. doi:.https://doi.org/10.1016/j.apmr.2003.08.085
  23. Feehan AG, Zacharin MR, Lim AS, Simm PJ. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood. Bone. 2018;113:137–43. doi:.https://doi.org/10.1016/j.bone.2018.05.021
  24. Balkefors V, Mattsson E, Pernow Y, Sääf M. Functioning and quality of life in adults with mild-to-moderate osteogenesis imperfecta. Physiother Res Int. 2013;18(4):203–11. doi:.https://doi.org/10.1002/pri.1546
  25. Tosi LL, Oetgen ME, Floor MK, Huber MB, Kennelly AM, McCarter RJ, et al. Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis. 2015;10(1):146. doi:.https://doi.org/10.1186/s13023-015-0362-2
  26. Wekre LL, Frøslie KF, Haugen L, Falch JA. A population-based study of demographical variables and ability to perform activities of daily living in adults with osteogenesis imperfecta. Disabil Rehabil. 2010;32(7):579–87. doi:.https://doi.org/10.3109/09638280903204690
  27. Van Brussel M, Takken T, Uiterwaal CS, Pruijs HJ, Van der Net J, Helders PJ, et al. Physical training in children with osteogenesis imperfecta. J Pediatr. 2008;152(1):111–6, 116.e1. doi:.https://doi.org/10.1016/j.jpeds.2007.06.029
  28. Dahan-Oliel N, Oliel S, Tsimicalis A, Montpetit K, Rauch F, Dogba MJ. Quality of life in osteogenesis imperfecta: A mixed-methods systematic review. Am J Med Genet A. 2016;170(1):62–76. doi:.https://doi.org/10.1002/ajmg.a.37377
  29. Shapiro JR, Germain-Lee EL. Osteogenesis imperfecta: effecting the transition from adolescent to adult medical care. J Musculoskelet Neuronal Interact. 2012;12(1):24–7.
  30. Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B. 2003;12(2):77–87.
  31. Montpetit K, Palomo T, Glorieux FH, Fassier F, Rauch F. Multidisciplinary Treatment of Severe Osteogenesis Imperfecta: Functional Outcomes at Skeletal Maturity. Arch Phys Med Rehabil. 2015;96(10):1834–9. doi:.https://doi.org/10.1016/j.apmr.2015.06.006
  32. Tsimicalis A, Denis-Larocque G, Michalovic A, Lepage C, Williams K, Yao TR, et al. The psychosocial experience of individuals living with osteogenesis imperfecta: a mixed-methods systematic review. Qual Life Res. 2016;25(8):1877–96. doi:.https://doi.org/10.1007/s11136-016-1247-0

Most read articles by the same author(s)